Antibody-drug conjugates (ADCs) are being explored as a potential treatment for lung cancer, with some studies suggesting they could replace chemotherapy or be used as an earlier intervention. The role of ADCs in lung cancer treatment is being discussed at various conferences and in medical publications, with some focusing on their use in specific types of lung cancer. The development of ADCs is also being considered in the context of broader cancer treatment advancements, with potential implications for other types of cancer.